Effects of interferon-γ in T cell subsets of mice infected with <i>Toxoplasma gondii</i>

, Lee, Y H; , Na, Y E; , Shin, D W

doi:1993.31.1.31

Korean J Parasito > Volume 31(1):1993 > Article

Original Article


Korean J Parasitol. 1993 Mar;31(1):31-36. English. Published online Mar 20, 1994. http://dx.doi.org/10.3347/kjp.1993.31.1.31
Copyright © 1993 by The Korean Society for Parasitology


Effects of interferon-γ in T cell subsets of mice infected with Toxoplasma gondii
Young-Ha Lee,^*Young-Eun Na and Dae-Whan Shin
Department of Parasitology, College of Medicine, Chungnam National University, Taejon 301-131, Korea.

Received January 06, 1993; Accepted January 26, 1993.

Abstract
This study was performed to evaluate differences of T cell subsets according to the injection period of recombinant mouse interferon-γ (IFN-γ) in acute Toxoplasma gondii infection. Each mouse was infected intraperitoneally with 100 cysts of Beverley strain T. gondii, and injected with 5 × 10⁴ units of IFN-γ every other day two tmres. The percentage of Thy-1,2 cells and L3T4/Ly-2 cell ratio were significantly increased in the mice that received two doses of IFN-γ on days 2 and 0 before infection, or days 0 and 2 after infection. The percentage of Ly-2 cells decreased in the IFN-γ injected groups at the 3rd and 4th week after infection. The results suggest that administration of IFN-γ to T. gondii-infected mice improves the changed population of T cell subsets to a normal state, especially when IFN-γ was injected just after the infection.

Figures


	Fig. 1 L3T4/Ly-2 cell ratio of splenocytes in Toxoplasma gondii-infected mice after IFN-γ injection in case that T cell ratio of infected control sets 1.00. Each symbol represents the mean of 3 mice.

Tables


	Table 1 Percentage of Thy-1,2 cells (total T cells) of splenocytes in Toxoplasma gondii-infected mice after IFN-γ injection^a)


	Table 2 Percentage of L3T4 cells (helper/inducer T cells) of splenocytes in Toxoplasma gondii-infected mice after IFN-γ injection


	Table 3 Percentage of Ly-2 cells (cytotoxic/suppressor T cells) of splenocytes in Toxoplasma gondii-infected mice after IFN-γ injection

References


2.	Carney WP, Iacoviello V, Hirsch MS. Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J Immunol 1983;130(1):390–393.

3.	Centers for Disease Control (CDC). Update: acquired immunodeficiency syndrome--United States. MMWR Morb Mortal Wkly Rep 1986;35(2):17–21.

4.	De Waele M, Thielemans C, Van Camp BK. Characterization of immunoregulatory T cells in EBV-induced infectious mononucleosis by monoclonal antibodies. N Engl J Med 1981;304(8):460–462.

5.	Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasmagondii vaccine. J Immunol 1991;146(1):286–292.

6.	Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 1992;149(1):175–180.

7.	Goyal M, Ganguly NK, Mahajan RC. Immunological response in experimentally reactivated toxoplasmosis in mice. Med Microbiol Immunol 1989;178(5):269–278.

8.	Herberman RB. Design of clinical trials with biological response modifiers. Cancer Treat Rep 1985;69(10):1161–1164.

9.	Hofflin JM, Remington JS. In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii. Antimicrob Agents Chemother 1987;31(2):346–348.

*10.*	Hooper DC, Pruitt AA, Rubin RH. Central nervous system infection in the chronically immunosuppressed. Medicine (Baltimore) 1982;61(3):166–188.

*11.*	Jones TC, Alkan S, Erb P. Spleen and lymph node cell populations, in vitro cell proliferation and interferon-gamma production during the primary immune response to Toxoplasma gondii. Parasite Immunol 1986;8(6):619–629.

*12.*	Jones TC, Alkan S, Erb P. Murine spleen and lymph node cellular composition and function during cyclophosphamide and splenectomy induced resistance to Toxoplasma gondii. Parasite Immunol 1987;9(1):117–131.

*13.*	Khan IA, Ely KH, Kasper LH. A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. J Immunol 1991;147(10):3501–3506.

*14.*	McCabe RE, Luft BJ, Remington JS. Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis 1984;150(6):961–962.

*15.*	McLeod R, Eisenhauer P, Mack D, Brown C, Filice G, Spitalny G. Immune responses associated with early survival after peroral infection with Toxoplasma gondii. J Immunol 1989;142(9):3247–3255.

*16.*	Schellekens H. Animal models in interferon research: some current trends. Experientia 1989;45(6):558–562.

*17.*	Sklenar I, Jones TC, Alkan S, Erb P. Association of symptomatic human infection with Toxoplasma gondii with imbalance of monocytes and antigen-specific T cell subsets. J Infect Dis 1986;153(2):315–324.

*18.*	Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988;240(4851):516–518.

*19.*	Suzuki Y, Conley FK, Remington JS. Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon. Infect Immun 1990;58(9):3050–3055.

*20.*	Yano A, Norose K, Yamashita K, Aosai F, Sugane K, Segawa K, Hayashi S. Immune response to Toxoplasma gondii--analysis of suppressor T cells in a patient with symptomatic acute toxoplasmosis. J Parasitol 1987;73(5):954–961.